News

Johnson & Johnson today announced that they will acquire all outstanding shares of Intra-Cellular Therapies, as well as their therapeutic pipeline, including lumateperone.

How can you manage health care coordination for patients who traverse various levels of care?

The LA fires demonstrate the incredibly difficult process of loss and grieving past selves…

Learn more about the latest research on different approaches to treatments for major depressive disorder (MDD).

From navigating crises to championing inclusive, patient-centered care, psychiatric leaders are redefining mental health policies, dismantling stigma, and driving transformative change across communities.

Check out these examples of neuroplasticity.

What actions can mental health clinicians take to reduce climate instability?

Jessi Gold, MD, MS, writes about the emotional challenges of healthcare during the COVID-19 pandemic. Through patient stories and her own reflections, she uncovers what happens when clinicians are asked to "feel."

How can we optimize and expand our knowledge of neuroplasticity?

The winner of the Chrismukkah essay contest is…

Join us in congratulating Dr Tasman on his recent win of the Hartford HealthCare Institute of Living’s 2024 C. Charles Burlingame, MD, award.

Welcome to the year-long celebration.

The FDA has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody being investigated for the treatment of patients with early Alzheimer disease.

Check out the positive topline results from a phase 2 dose finding trial evaluating N-methyl amisulpride (LB-102) in adult patients with acute schizophrenia.

There is no accurate profile of who will become a school shooter, so mental health clinicians should react as they would with any patient threatening violence: inquire, gain collateral data, assess, and respond.

Bipolar I disorder (BD-I) can be difficult to diagnose and treat due to overlapping symptoms and stigma. What can clinicians utilize to help manage BD-I for better long-term outcomes?

Nuclear war capability: why we should be worried psychiatrically.

Do you want to be featured in a future Special Report? Check out our January theme!

How can psychiatric clinicians ensure their practices are accessible to patients with disabilities?

Psychiatric Times: Supporting clinicians, promoting conversations, and improving patient care over the past 40 years.

How much fear is too much?

How will the definition of assisted death (AD) as medical care impact its utilization?

Essay contest winners will be announced on January 6th.

The final installment in this journal on ketamine.

Navacaprant for the treatment of major depressive disorder has failed in the phase 3 KOASTAL-1 trial.

A psychiatrist reflects on the New Year and its potential...

We asked our contributors at the 63rd meeting of the American College of Neuropsychopharmacology what they are excited about from 2024 and what they are looking forward to in 2025. Here's what they said.

How do your fellow clinicians feel about the holidays? Are they feeling the effects of burnout heading into 2025? Find out here.

Let's review the Special Reports of 2024!